Download Files:
LY-2584702 (tosylate salt)
$90 – $650
Products Details
Product Description
– LY-2584702 tosylate salt is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
Web ID
– HY-12493A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C28H27F4N7O3S
Citations
– Hepatology. 2022 Sep 21.|Immunity. 2021 Sep 14;54(9):2042-2056.e8.|Pharmacol Res. 2021 Oct 4;105871.|Theranostics. 2022 Jan 1;12(3):1204-1219.|Harvard Medical School LINCS LIBRARY
References
– [1]Phung TL, et al. Akt1 and akt3 exert opposing roles in the regulation of vascular tumor growth. Cancer Res. 2015 Jan 1;75(1):40-50.|[2]Chen B, et al. Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients. PLoS One. 2017 Aug 9;12(8):e0182891.|[3]Tolcher A, et al. A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumors. Eur J Cancer. 2014 Mar;50(5):867-75.
CAS Number
– 1082949-68-5
Molecular Weight
– 617.62
Compound Purity
– 98.58
SMILES
– CN1C=C(C2=CC=C(F)C(C(F)(F)F)=C2)N=C1C3CCN(C4=C5C(NN=C5)=NC=N4)CC3.O=S(C6=CC=C(C)C=C6)(O)=O
Clinical Information
– Phase 1
Research Area
– Cancer
Solubility
– DMSO : 10.25 mg/mL (ultrasonic;warming)
Target
– Ribosomal S6 Kinase (RSK)
Isoform
– p70S6K
Pathway
– MAPK/ERK Pathway
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
